Related Experiment Video
Updated: Jul 2, 2026
07:19
A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms
Published on: October 21, 2010
Surveillance for Candida auris - United States, 2022-2024
Morbidity and Mortality Weekly Report. Surveillance Summaries (Washington, D.C. : 2002)
|June 30, 2026
Summary
The number of Candida auris (C. auris) cases reported in the U.S. increased from 2022 to 2024, highlighting ongoing transmission in healthcare settings. Continued infection control and surveillance are crucial to combat this drug-resistant yeast.
Area of Science:
- Infectious Diseases
- Public Health Surveillance
- Antimicrobial Resistance
Background:
- Candida auris (C. auris) is an emerging, multidrug-resistant yeast causing invasive infections with high mortality.
- C. auris asymptomatically colonizes patients, facilitating healthcare-associated transmission.
- National monitoring of C. auris cases is vital for effective infection prevention and control.
Purpose of the Study:
- To analyze national trends in clinical and screening cases of Candida auris reported to the CDC between 2022 and 2024.
- To understand the epidemiology and healthcare-associated transmission patterns of C. auris in the U.S.
Main Methods:
- Voluntary reporting of clinical and screening C. auris cases by state and jurisdictional health departments to the CDC.
- Data collected through REDCap or DCIPHER platforms, including patient demographics, case type, specimen source, and facility type.
- Descriptive analyses limited to cases with specimen collection dates from 2022 to 2024.
Main Results:
- Total reported C. auris cases increased from 9,110 in 2022 to 13,625 in 2023 and 20,129 in 2024.
- Clinical cases rose from 2,882 in 2022 to 6,197 in 2024; screening cases increased from 6,226 in 2022 to 12,432 in 2024.
- Most cases occurred in adults aged ≥45 years; acute care hospitals showed an increasing proportion for screening case specimen collection.
Conclusions:
- The rising number of reported C. auris cases indicates persistent transmission within U.S. healthcare settings.
- Sustained infection prevention and control measures, including enhanced screening and disinfection, are essential.
- Continued investment in surveillance, laboratory capacity, and antifungal susceptibility testing is critical to combat C. auris spread and resistance.
Related Concept Videos
01:22Healthcare Associated Infections II: Preventive Measures
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
01:26Principles of Disease Surveillance
Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:23Investigation of Disease Outbreaks
Multistate foodborne outbreaks pose significant public health risks and require meticulous investigation to identify sources and implement control measures. The Centers for Disease Control and Prevention (CDC) utilizes a dynamic seven-step process for these investigations, integrating data from laboratories, interviews, and environmental assessments to protect public health.Outbreak Detection: The detection of multistate outbreaks typically begins with PulseNet, the CDC's national laboratory...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...